Precigen (PGEN) Gains FDA Platform Backing As Its Valuation Story Gets Harder To Ignore
Precigen (PGEN) drew fresh attention after the FDA granted platform technology designation to its AdenoVerse immunotherapy platform, which underpins PAPZIMEOS and could streamline future programs and regulatory interactions.
Recent trading suggests investors are starting to price in this shift. Precigen’s share price return is up 32.25% over the past 90 days and 81.07% year to date, while the 1-year total shareholder return of 120.80% points to strong longer term momentum from a relatively low base.
Scan how the Precigen story fits into a wider gene and cell therapy opportunity set by comparing it with 38 healthcare AI stocks on similar regulatory and commercial catalysts.
Precigen now has a commercial product, a platform the FDA has formally recognized, and a share price that has already moved sharply. The key question is whether that story is already reflected in the price or still misaligned.
Most Popular Narrative: 43% Undervalued
Precigen’s most followed narrative pegs fair value at $13.65, well above the recent $7.75 close. This view places considerable emphasis on PAPZIMEOS and the broader AdenoVerse platform delivering against ambitious long term targets set under a 7.54% discount rate.
A potential transition to cash flow breakeven funded by current cash plus projected PAPZIMEOS revenues, alongside a simplified capital structure with preferred shares converted to common, could limit dilution risk and allow operating leverage to flow through to earnings as SG and A launch spending normalizes.
See why 12 investors see Precigen as 43% undervalued.
Result: Fair Value of $13.65 (UNDERVALUED)
Still, Precigen’s story leans heavily on PAPZIMEOS sustaining its early commercial traction. Any slower adoption or pricing pressure could quickly challenge that 43% undervalued narrative.
Find out about the key risks to this Precigen narrative.
Another View: Precigen Looks Expensive On Sales
While the Precigen story screens as undervalued on fair value models, the simple sales multiple tells a very different story. The stock trades on a P/S of 32.4x, compared with 12.1x for the US Biotechs industry, around 10x for close peers, and a fair ratio of 9.5x. That gap implies the market already prices in a lot of future execution. The real question is how much optimism you are willing to pay for.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Plenty in this Precigen story points in different directions, so move fast to review both sides of the ledger for yourself and weigh up the 2 key rewards and 3 important warning signs.
Looking for more Precigen sized ideas?
If Precigen has caught your eye, do not stop here. Widen your watchlist with fresh opportunities that fit clear, focused return profiles.
- Target strong value potential by scanning companies that screen as high quality and potentially underpriced through the 32 high quality undervalued stocks.
- Prioritize resilience first by zeroing in on businesses with robust finances using the list of solid balance sheet and fundamentals (24 results).
- Hunt for under-the-radar opportunities by reviewing a curated pool of promising outliers via the 16 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com